| [1] |
|
| [2] |
Fan Z, Li H, Hu R, et al. Fertility-preserving treatment in young women with grade 1 presumed stage IA endometrial adenocarcinoma: A Meta-analysis [J]. Int J Gynecol Cancer, 2018, 28(2): 385-393. DOI: 10.1097/IGC.0000000000001164.
|
| [3] |
Gonthier C, Douhnai D, Koskas M. Lymph node metastasis probability in young patients eligible for conservative management of endometrial cancer [J]. Gynecol Oncol, 2020, 157(1): 131-135. DOI： 10.1016/j.ygyno.2020.02.021.
|
| [4] |
Peters EEM, León-Castillo A, Smit VTHBM, et al. Defining substantial lymphovascular space invasion in endometrial cancer [J]. Int J Gynecol Pathol, 2022, 41(3): 220-226. DOI: 10.1097/PGP.0000000000000806.
|
| [5] |
Raffone A, Travaglino A, Raimondo D, et al. Lymphovascular space invasion in endometrial carcinoma: a prognostic factor independent from molecular signature [J]. Gynecol Oncol, 2022, 165(1): 192-197. DOI: 10.1016/j.ygyno.2022.01.013.
|
| [6] |
Koskas M, Amant F, Mirza MR, et al. Cancer of the corpus uteri: 2021 update [J]. Int J Gynaecol Obstet, 2021, 155(Suppl 1): 45-60. DOI: 10.1002/ijgo.13866.
|
| [7] |
|
| [8] |
Nicole C, Xavier GM, Ignace V, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma [J]. Int J Gynecol Cancer, 2020, 31(1): 12-39. DOI： 10.1136/IJGC-2020-002230.
|
| [9] |
Watanabe T, Honma R, Kojima M, et al. Prediction of lymphovascular space invasion in endometrial cancer using the 55-gene signature selected by DNA microarray analysis [J]. PLoS One, 2019, 14(9): e0223178. DOI: 10.1371/journal.pone.0223178.
|
| [10] |
Li Y, Qu J, Sun Y, et al. Troponin T1 promotes the proliferation of ovarian cancer by regulating cell cycle and apoptosis [J]. Iran J Biotechnol, 2023, 21(1): e3405. DOI: 10.30498/ijb.2022.344921.3405.
|
| [11] |
Mannelqvist M, Stefansson IM, Bredholt G, et al. Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer [J]. Am J Pathol, 2011, 178(2): 861-871. DOI: 10.1016/j.ajpath.2010.10.040.
|
| [12] |
Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma [J]. Int J Gynecol Cancer, 2021, 31(1): 12-39. DOI: 10.1136/ijgc-2020-002230.
|
| [13] |
Yang BH, Yu MX, Xu J, et al. The value of DNA quantitative cytology test for the screening of endometrial cancer [J]. Cancer Manag Res, 2019， 11: 10383-10391. DOI: 10.2147/CMAR.S225672.
|
| [14] |
Svanvik T, Strmberg U, Holmberg E, et al. DNA ploidy status, S-phase fraction, and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage I-III [J]. Int J Gynecol Cancer, 2019, 29(2): 305-311. DOI: 10.1136/ijgc-2018-000082.
|
| [15] |
Patthey A, Boman K, Tavelin B, et al. Combination of aneuploidy and high S-phase fraction indicates increased risk of relapse in stage I endometrioid endometrial carcinoma [J]. Acta Oncol, 2021, 60(9): 1218-1224. DOI: 10.1080/0284186X.2021.1939146.
|
| [16] |
Bolivar AM, Luthra R, Mehrotra M，et al. Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients [J]. Mod Pathol, 2019, 32(3): 405-414. DOI: 10.1038/s41379-018-0158-8.
|
| [17] |
Ronchetti L, Terrenato I, Ferretti M, et al. Circulating cell free DNA and citrullinated histone H3 as useful biomarkers of NETosis in endometrial cancer [J]. J Exp Clin Cancer Res, 2022, 41(1): 151. DOI: 10.1186/s13046-022-02359-5.
|
| [18] |
Vizza E, Corrado G, De Angeli M, et al. Serum DNA integrity index as a potential molecular biomarker in endometrial cancer [J]. J Exp Clin Cancer Res, 2018, 37(1): 16. DOI： 10.1186/s13046-018-0688-4.
|
| [19] |
Gressel GM, Maggi EC, Harmon BE, et al. Low molecular weight serum cell-free DNA concentration is associated with clinicopathologic indices of poor prognosis in women with uterine cancer [J]. J Transl Med, 2020， 18(1): 323. DOI： 10.1186/s12967-020-02493-8.
|
| [20] |
Shintani D, Hihara T, Ogasawara A, et al. Tumor-related mutations in cell-free DNA in preoperative plasma as a prognostic indicator of recurrence in endometrial cancer [J]. Int J Gynecol Cancer, 2020, 30(9): 1340-1346. DOI: 10.1136/ijgc-2019-001053.
|
| [21] |
Zhou H, Gao Z, Wan F. Taurine-upregulated gene 1 contributes to cancers through sponging microRNA [J]. Acta Biochim Biophys Sin (Shanghai), 2019, 51(2): 123-130. DOI: 10.1093/abbs/gmy156.
|
| [22] |
Chen Q, Schatz C, Cen Y, et al. LncRNA TUG1 promotes the migration and invasion in type I endometrial carcinoma cells by regulating E-N cadherin switch [J]. Taiwan J Obstet Gynecol, 2022, 61(5): 780-787. DOI: 10.1016/j.tjog.2022.03.045.
|
| [23] |
Metovic J, Borella F, D′Alonzo M, et al. FOXA1 in breast cancer: a luminal marker with promising prognostic and predictive impact [J]. Cancers (Basel), 2022, 14(19): 4415-4421. DOI： 10.3390/cancers14194699.
|
| [24] |
Yildiz ON, Topal CS, Zemheri IE. Diagnostic importance of PAX2, ARID1A, and FOXA1 biomarkers in atypical endometrial hyperplasia [J]. J Coll Physicians Surg Pak, 2023, 33(8): 847-851. DOI: 10.29271/jcpsp.2023.08.847.
|
| [25] |
Tosun YH, Nergiz D, Sadullaho？lu C, et al. FOXA1 is associated with high tumor grade, myometrial invasion and lymph node invasion in endometrial endometrioid carcinoma [J]. Ginekol Pol, 2021, 92(8): 544-549. DOI: 10.5603/GP.a2021.0016.
|
| [26] |
Young MJ, Sachidanandam R, Hales DB, et al. Identification of somatic mitochondrial DNA mutations, heteroplasmy, and increased levels of catenanes in tumor specimens obtained from three endometrial cancer patients [J]. Life (Basel), 2022, 12(4): 562. DOI: 10.3390/life12040562.
|
| [27] |
Xu J, Wang X, Du Q, et al. Clinical significance of lymphatic infiltration detected by immunohistochemical double staining in patients with endometrial cancer [J]. Clin Med Insights Oncol, 2023, 17: 11795549231152308.
|
| [28] |
Stewart CL, Warner S, Ito K, et al. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? [J]. Curr Probl Surg, 2018, 55(9): 330-379. DOI: 10.1067/j.cpsurg.2018.08.004.
|
| [29] |
Kim SI, Yoon JH, Lee SJ, et al. Prediction of lymphovascular space invasion in patients with endometrial cancer [J]. Int J Med Sci, 2021, 18(13): 2828-2834. DOI： 10.7150/ijms.60718.
|
| [30] |
Meydanli MM, Aslan K, Öz M, et al. Is it possible to develop a prediction model for lymphovascular space invasion in endometrioid endometrial cancer? [J]. Int J Gynecol Pathol, 2020, 39(3): 213-220. DOI： 10.1097/pgp.0000000000000596.
|
| [31] |
Celli V, Guerreri M, Pernazza A, et al. MRI- and histologic-molecular-based radio-genomics nomogram for preoperative assessment of risk classes in endometrial cancer [J]. Cancers (Basel), 2022, 14(23): 5881. DOI: 10.3390/cancers14235881.
|
| [32] |
Capozzi VA, Sozzi G, Uccella S, et al. Novel preoperative predictive score to evaluate lymphovascular space involvement in endometrial cancer: an aid to the sentinel lymph node algorithm [J]. Int J Gynecol Cancer, 2020, 30(6): 806-812. DOI： 10.1136/ijgc-2019-001016.
|
| [33] |
Luo Y, Mei D, Gong J, et al. Multiparametric MRI-based radiomics nomogram for predicting lymphovascular space invasion in endometrial carcinoma [J]. J Magn Reson Imaging, 2020, 52(4): 1257-1262. DOI： 10.1002/jmri.27142.
|
| [34] |
Berek JS, Matias-Guiu X. FIGO endometrial cancer staging subcommittee, FIGO Women′s Cancer Committee. Response: FIGO staging of endometrial cancer: 2023 [J]. Int J Gynaecol Obstet, 2023, 7: 1-12. DOI： 10.1002/IJGO.15046.
|